Target organ damage in hypertension: Pathophysiology and implications for drug therapy

Sunil K. Nadar, Muzahir H. Tayebjee, Franz Messerli, Gregory Y H Lip

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

Hypertension is a well known risk factor for cardiovascular and cerebrovascular events such as heart attacks and strokes. In addition, it is associated with earlier changes in organ systems in the body, such as left ventricular hypertrophy (LVH), proteinuria and renal failure, retinopathy and vascular dementia which are grouped under the term "target organ damage"(TOD). There are many processes involved in the pathogenesis of TOD and these include endothelial activation, platelet activation, increased thrombogenesis, changes in the renin aldosterone angiotensin system (RAAS), and collagen turnover. All these changes work hand in hand and lead to the production of hypertensive TOD. In this review, we aim to provide an overview of the recent advances in pathophysiology of hypertensive TOD, and examine how these changes lead to the production of TOD. A better understanding of these pathogenic processes would help us better devise treatment strategies in preventing the dreaded complications associated with hypertension.

Original languageEnglish
Pages (from-to)1581-1592
Number of pages12
JournalCurrent Pharmaceutical Design
Volume12
Issue number13
DOIs
Publication statusPublished - May 2006

Fingerprint

Hypertension
Drug Therapy
Vascular Dementia
Platelet Activation
Left Ventricular Hypertrophy
Renin-Angiotensin System
Proteinuria
Renal Insufficiency
Collagen
Stroke
Myocardial Infarction
Therapeutics

Keywords

  • Endothelial activation
  • Hypertension
  • Platelet activation
  • Target organ damage

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Target organ damage in hypertension : Pathophysiology and implications for drug therapy. / Nadar, Sunil K.; Tayebjee, Muzahir H.; Messerli, Franz; Lip, Gregory Y H.

In: Current Pharmaceutical Design, Vol. 12, No. 13, 05.2006, p. 1581-1592.

Research output: Contribution to journalReview article

Nadar, Sunil K. ; Tayebjee, Muzahir H. ; Messerli, Franz ; Lip, Gregory Y H. / Target organ damage in hypertension : Pathophysiology and implications for drug therapy. In: Current Pharmaceutical Design. 2006 ; Vol. 12, No. 13. pp. 1581-1592.
@article{3a9f934235334f9b972409697e71570e,
title = "Target organ damage in hypertension: Pathophysiology and implications for drug therapy",
abstract = "Hypertension is a well known risk factor for cardiovascular and cerebrovascular events such as heart attacks and strokes. In addition, it is associated with earlier changes in organ systems in the body, such as left ventricular hypertrophy (LVH), proteinuria and renal failure, retinopathy and vascular dementia which are grouped under the term {"}target organ damage{"}(TOD). There are many processes involved in the pathogenesis of TOD and these include endothelial activation, platelet activation, increased thrombogenesis, changes in the renin aldosterone angiotensin system (RAAS), and collagen turnover. All these changes work hand in hand and lead to the production of hypertensive TOD. In this review, we aim to provide an overview of the recent advances in pathophysiology of hypertensive TOD, and examine how these changes lead to the production of TOD. A better understanding of these pathogenic processes would help us better devise treatment strategies in preventing the dreaded complications associated with hypertension.",
keywords = "Endothelial activation, Hypertension, Platelet activation, Target organ damage",
author = "Nadar, {Sunil K.} and Tayebjee, {Muzahir H.} and Franz Messerli and Lip, {Gregory Y H}",
year = "2006",
month = "5",
doi = "10.2174/138161206776843368",
language = "English",
volume = "12",
pages = "1581--1592",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Target organ damage in hypertension

T2 - Pathophysiology and implications for drug therapy

AU - Nadar, Sunil K.

AU - Tayebjee, Muzahir H.

AU - Messerli, Franz

AU - Lip, Gregory Y H

PY - 2006/5

Y1 - 2006/5

N2 - Hypertension is a well known risk factor for cardiovascular and cerebrovascular events such as heart attacks and strokes. In addition, it is associated with earlier changes in organ systems in the body, such as left ventricular hypertrophy (LVH), proteinuria and renal failure, retinopathy and vascular dementia which are grouped under the term "target organ damage"(TOD). There are many processes involved in the pathogenesis of TOD and these include endothelial activation, platelet activation, increased thrombogenesis, changes in the renin aldosterone angiotensin system (RAAS), and collagen turnover. All these changes work hand in hand and lead to the production of hypertensive TOD. In this review, we aim to provide an overview of the recent advances in pathophysiology of hypertensive TOD, and examine how these changes lead to the production of TOD. A better understanding of these pathogenic processes would help us better devise treatment strategies in preventing the dreaded complications associated with hypertension.

AB - Hypertension is a well known risk factor for cardiovascular and cerebrovascular events such as heart attacks and strokes. In addition, it is associated with earlier changes in organ systems in the body, such as left ventricular hypertrophy (LVH), proteinuria and renal failure, retinopathy and vascular dementia which are grouped under the term "target organ damage"(TOD). There are many processes involved in the pathogenesis of TOD and these include endothelial activation, platelet activation, increased thrombogenesis, changes in the renin aldosterone angiotensin system (RAAS), and collagen turnover. All these changes work hand in hand and lead to the production of hypertensive TOD. In this review, we aim to provide an overview of the recent advances in pathophysiology of hypertensive TOD, and examine how these changes lead to the production of TOD. A better understanding of these pathogenic processes would help us better devise treatment strategies in preventing the dreaded complications associated with hypertension.

KW - Endothelial activation

KW - Hypertension

KW - Platelet activation

KW - Target organ damage

UR - http://www.scopus.com/inward/record.url?scp=33646506871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646506871&partnerID=8YFLogxK

U2 - 10.2174/138161206776843368

DO - 10.2174/138161206776843368

M3 - Review article

C2 - 16729871

AN - SCOPUS:33646506871

VL - 12

SP - 1581

EP - 1592

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 13

ER -